Tests a new drug added to chemotherapy for advanced bowel cancer
Tests INCA33890 with chemotherapy and bevacizumab in adults with advanced colorectal cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Key facts
- Where
- Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Hohhot, Jinan, Jining, Jinzhou, Lanzhou, Meizhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, and Xi'an, ChinaSee the 29 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV colorectal cancer that has spread and cannot be removed by surgery, and who have not yet had treatment for it.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Stage IV colorectal adenocarcinoma that cannot be removed by surgery meant to remove all of the disease. The disease must be measurable on scans (RECIST v1.1). Performance status (ECOG) of 0 or 1. Organ function must be adequate on lab tests.
- Earlier treatment
- No earlier systemic treatment for cancer that cannot be removed or has spread. Treatment given before or after surgery is allowed if the cancer did not return within 12 months of the end of that treatment.
- Biomarker or test result
- The cancer must be microsatellite stable (MSS). Tumours with MSI-H/dMMR or a BRAF V600E mutation, as shown in the medical record, are not allowed.
Main reasons for not taking part
- Brain or spinal cord (CNS) metastases that are untreated or growing
- Another cancer within the past 2 years
- Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor in the last 3 years
- Active autoimmune disease that needed systemic treatment in the past 2 years
- Earlier organ transplant, including stem cell transplant from a donor
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
- Has a test of your tumour shown a change (mutation) in the KRAS, NRAS or BRAF genes?
- Has a test shown that your tumour is 'MSI-high' or 'dMMR'?
- Which best describes how well you can look after yourself and be active?
Source: NCT07284849, who can take part
Where in China
- Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaNot yet recruiting
- Peking University First HospitalBeijing, ChinaNot yet recruiting
- Xiangya Hospital Central South UniversityChangsha, ChinaNot yet recruiting
- Sichuan Cancer HospitalChengdu, ChinaNot yet recruiting
- Chongqing University Cancer HospitalChongqing, ChinaNot yet recruiting
- The First People's Hospital of FoshanFoshan, ChinaNot yet recruiting
- Fujian Medical University Union HospitalFuzhou, ChinaNot yet recruiting
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaNot yet recruiting
- The Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, ChinaNot yet recruiting
- Zhujiang Hospital of Southern Medical UniversityGuangzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of Zhejiang UniversityHangzhou, ChinaNot yet recruiting
- The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaNot yet recruiting
- University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital)Hefei, ChinaNot yet recruiting
- Inner Mongolia People's HospitalHohhot, ChinaNot yet recruiting
- Jinan Central HospitalJinan, ChinaNot yet recruiting
- Affiliated Hospital of Jining Medical UniversityJining, ChinaNot yet recruiting
- The First Affiliated Hospital of Jinzhou Medical UniversityJinzhou, ChinaNot yet recruiting
- The First Hospital of Lanzhou UniversityLanzhou, ChinaNot yet recruiting
- Meizhou Peoples HospitalMeizhou, ChinaNot yet recruiting
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNot yet recruiting
- Guangxi Medical University Affiliated Tumor HospitalNanning, ChinaNot yet recruiting
- Fudan University Shanghai Cancer CenterShanghai, ChinaNot yet recruiting
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaNot yet recruiting
- The Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaNot yet recruiting
- Tianjin Medical University Cancer Institute & HospitalTianjin, ChinaNot yet recruiting
- The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNot yet recruiting
- Hubei Cancer HospitalWuhan, ChinaNot yet recruiting
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhan, ChinaNot yet recruiting
- Shaanxi provincial people's hospitalXi'an, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07284849EU 2025-523735-19-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.Read full original descriptionShow less
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Inclusion: Stage IV colorectal adenocarcinoma not amenable to curative resection; No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment; Measurable disease per RECIST v1.1; ECOG performance status of 0 or 1; Adequate organ function determined by laboratory results.
Exclusion: Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years; Significant concurrent and/or uncontrolled medical condition; History of other malignancy within 2 years; Active autoimmune disease that has required systemic treatment in the past 2 years; History of organ transplant, including allogeneic stem cell transplantation; Other protocol-defined inclusion/exclusion criteria apply; MSI-H/dMMR per historical data in the medical record; BRAF V600E mutation per historical data in the medical record; Untreated and/or progressing CNS metastases.